• Surgical Oncologist, Department of Surgery, CHUM
  • Scotiabank Chair in Breast Cancer Diagnosis and Treatment, Université de Montréal
  • Administrative Director of the Clinical Breast Cancer Research Team (GRCS), CHUM
  • Associate Professor, Department of Surgery, Faculty of Medicine, Université de Montréal
  • Research member, Montreal Cancer Institute

Research Themes

  • Translational Research – laboratory based
    • Triple-negative breast cancer
    • PARP inhibitors, identification of predictive biomarkers and new combination therapies
    • Inhibiting the development of metastasis
  • Clinical Research
    • In affiliation with cooperative groups such as NRG Oncology, NSABP, and McPeak Sirois Group of Quebec, and industry-sponsored trials
    • Phase II and III trials in neoadjuvant, adjuvant and metastatic settings
    • Investigator-initiated studies

Recent Grants

  • NanoString GeoMX Oncology grant : spatial biology application for whole transcriptome analysis in triple-negative breast cancer, May 2023
  • Breast Cancer Canada Precision Oncology grant, “Disentangling the genomic and immune landscape to predict response to PARP inhibition and immunotherapy in triple-negative breast cancer”, May 2023

Recent Publications

  1. Hassan S, Gray JW, Heiser LM. Systems Biology and Genomics, Book Chapter In: Holland-Frei Cancer Medicine, 10th Edition (RC Bast Jr, JC Byrd, CC Croce, E Hawk, FR Khuri, RE Pollock, A-M Tsimberidou, CG Willett, CL Willman, eds.) John Wiley & Sons, Inc., Hoboken, N.J., April 2023. https://www.wiley.com/en-us/Holland+Frei+Cancer+Medicine%2C+10th+Edition-p-9781119750703#author-section.
  2. Beniey M, Hubert A, Haque T, Cotte A, Bechir N, Zhang X, Tran-Thanh D, Hassan S. Sequential targeting of PARP with carboplatin inhibits primary tumor growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023 Mar 20 https://www.nature.com/articles/s41416-023-02226-w
  3. Hassan S, Younan R, Patocskai E, Provencher L, Poirier B, Sideris L, Dubé P, Mihalcioiu C, Chabot-Blanchet M, Guertin M-C, Boileau J-F, Robidoux A. Impact of the 21-Gene Breast Recurrence Score on Treatment Decisions and Cost in Patients with Node-Positive breast cancer: a Multicenter study in Quebec. Oncologist. 2022 Oct 1 : 13:oyac123. doi: 10.1093/oncolo/oyac123
  4. Yordanova M, Hassan S. The role of the 21-gene Recurrence Score in hormone-receptor positive, node-positive breast cancer: the Canadian experience.  Current Oncology 2022, 29(3), 2008-2020; https://doi.org/10.3390/curroncol29030163
  5. Schmid P, Cortes J, Dent R, et al. and KEYNOTE-522 Investigators. Event-Free survival with Pembrolizumab in Early Triple-Negative Breast Cancer. NEJM 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651
  6. Yordanova M, Hubert A, Hassan S. Expanding the use of PARP inhibitors as monotherapy and in combination in triple-negative breast cancer. Pharmaceuticals 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.

Complete list of publications can be found here: https://www.ncbi.nlm.nih.gov/myncbi/1ZMvOR5JrMBk2/bibliography/public/

Open positions

Currently accepting applications for:

  • MSc student
  • Post-doctoral research fellow

All interested applicants must send a cover letter and their CV to saima.hassan@umontreal.ca.